Format

Send to

Choose Destination
Future Oncol. 2017 Apr;13(8):727-741. doi: 10.2217/fon-2016-0229. Epub 2016 Nov 24.

Focal therapy as primary treatment for localized prostate cancer: definition, needs and future.

Author information

1
Department of Urology, CHRU de Lille, Hôpital Claude Huriez, F-59037 Lille, France.
2
NSERM, U1189, ONCO-THAI, F-59037 Lille, France.
3
Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
4
Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
5
Department of Urology, Hôpital Privé de la Louvière, Ramsay Générale de Santé, 59000 Lille, France.
6
Institut universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.
7
Department of Urology, Saint-Jean Languedoc Hospital, Toulouse, France.

Abstract

Focal therapy (FT) may offer a promising treatment option in the field of low to intermediate risk localized prostate cancer. The aim of this concept is to combine minimal morbidity with cancer control as well as maintain the possibility of retreatment. Recent advances in MRI and targeted biopsy has improved the diagnostic pathway of prostate cancer and increased the interest in FT. However, before implementation of FT in routine clinical practice, several challenges are still to overcome including patient selection, treatment planning, post-therapy monitoring and definition of oncologic outcome surrogates. In this article, relevant questions regarding the key steps of FT are critically discussed and the main available energy modalities are analyzed taking into account their advantages and unmet needs.

KEYWORDS:

HIFU; MRI; ablation; cryotherapy; focal therapy; imaging; laser; prostate cancer; urologic/prostate; watchful waiting

PMID:
27882770
DOI:
10.2217/fon-2016-0229
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center